EVA1A and hepatocellular carcinoma: In the present study, we examined the role of miR-125b in the resistance of HCC cells to oxaliplatin treatment and elucidated a potential mechanism by which miR-125b decreases oxaliplatin resistance in HCC via the downregulation of its target EVA1A.